Literature DB >> 35760991

Biomaterials for Mimicking and Modelling Tumor Microenvironment.

Rupambika Das1, Javier G Fernandez2.   

Abstract

This chapter summarizes the current biomaterials and associated technologies used to mimic and characterize the tumor microenvironment (TME) for developing preclinical therapeutics. Research in conventional 2D cancer models systematically fails to provide physiological significance due to their discrepancy with diseased tissue's native complexity and dynamic nature. The recent developments in biomaterials and microfabrication have enabled the popularization of 3D models, displacing the traditional use of Petri dishes and microscope slides to bioprinters or microfluidic devices. These technologies allow us to gather large amounts of time-dependent information on tissue-tissue, tissue-cell, and cell-cell interactions, fluid flows, and biomechanical cues at the cellular level that were inaccessible by traditional methods. In addition, the wave of new tools producing unprecedented amounts of data is also triggering a new revolution in the development and use of new tools for analysis, interpretation, and prediction, fueled by the concurrent development of artificial intelligence. Together, all these advances are crystalizing a new era for biomedical engineering characterized by high-throughput experiments and high-quality data.Furthermore, this new detailed understanding of disease and its multifaceted characteristics is enabling the long searched transition to personalized medicine.Here we outline the various biomaterials used to mimic the extracellular matrix (ECM) and redesign the tumor microenvironment, providing a comprehensive overview of cancer research's state of the art and future.
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  3D models; Biomaterials; Cancer; Extra cellular matrix (ECM); Microfluidics; Tumor micro environment (TME)

Mesh:

Substances:

Year:  2022        PMID: 35760991     DOI: 10.1007/978-3-031-04039-9_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   3.650


  102 in total

1.  E2F is required to prevent inappropriate S-phase entry of mammalian cells.

Authors:  S He; B L Cook; B E Deverman; U Weihe; F Zhang; V Prachand; J Zheng; S J Weintraub
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 2.  CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.

Authors:  Shom Goel; Molly J DeCristo; Sandra S McAllister; Jean J Zhao
Journal:  Trends Cell Biol       Date:  2018-07-27       Impact factor: 20.808

3.  Genetic Redundancy, Functional Compensation, and Cancer Vulnerability.

Authors:  Matteo Cereda; Thanos P Mourikis; Francesca D Ciccarelli
Journal:  Trends Cancer       Date:  2016-03-28

Review 4.  Strategies for cancer vaccine development.

Authors:  Matteo Vergati; Chiara Intrivici; Ngar-Yee Huen; Jeffrey Schlom; Kwong Y Tsang
Journal:  J Biomed Biotechnol       Date:  2010-07-11

Review 5.  Cancer progression and the invisible phase of metastatic colonization.

Authors:  Christoph A Klein
Journal:  Nat Rev Cancer       Date:  2020-10-06       Impact factor: 60.716

Review 6.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

7.  A history of cancer chemotherapy.

Authors:  Vincent T DeVita; Edward Chu
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 8.  How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.

Authors:  Jonathan L Messerschmidt; George C Prendergast; Gerald L Messerschmidt
Journal:  Oncologist       Date:  2016-02-01

9.  Patterns of somatic mutation in human cancer genomes.

Authors:  Christopher Greenman; Philip Stephens; Raffaella Smith; Gillian L Dalgliesh; Christopher Hunter; Graham Bignell; Helen Davies; Jon Teague; Adam Butler; Claire Stevens; Sarah Edkins; Sarah O'Meara; Imre Vastrik; Esther E Schmidt; Tim Avis; Syd Barthorpe; Gurpreet Bhamra; Gemma Buck; Bhudipa Choudhury; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kris Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jon Hinton; Andy Jenkinson; David Jones; Andy Menzies; Tatiana Mironenko; Janet Perry; Keiran Raine; Dave Richardson; Rebecca Shepherd; Alexandra Small; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; Daniel P Cahill; David N Louis; Peter Goldstraw; Andrew G Nicholson; Francis Brasseur; Leendert Looijenga; Barbara L Weber; Yoke-Eng Chiew; Anna DeFazio; Mel F Greaves; Anthony R Green; Peter Campbell; Ewan Birney; Douglas F Easton; Georgia Chenevix-Trench; Min-Han Tan; Sok Kean Khoo; Bin Tean Teh; Siu Tsan Yuen; Suet Yi Leung; Richard Wooster; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2007-03-08       Impact factor: 49.962

10.  Development of three-dimensional collagen scaffolds with controlled architecture for cell migration studies using breast cancer cell lines.

Authors:  Jonathan J Campbell; Anke Husmann; Robert D Hume; Christine J Watson; Ruth E Cameron
Journal:  Biomaterials       Date:  2016-11-01       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.